We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.75 | 8.33% | 48.75 | 48.00 | 49.50 | 49.00 | 45.00 | 45.00 | 3,830,663 | 12:30:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.53 | 138.26M |
TIDMAVCT
RNS Number : 1108T
Avacta Group PLC
09 October 2017
09 October 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Director Dealing and Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, announces that application has been made for 5,311 new ordinary shares of 10p each (the "New Ordinary Shares") to be admitted to trading on AIM on 16 October 2017 ("Admission").
The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, Non-Executive Director of the Company, of New Ordinary Shares in accordance with the terms set out in the Company's announcement of 23 February 2016.
Following Admission, the total number of ordinary shares with voting rights in issue will be 68,403,244. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Enquiries:
Avacta Group plc Tel: +44 (0) Alastair Smith, Chief Executive 844 414 0452 Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) Geoff Nash / Giles Rolls - Nominated 207 220 0500 Adviser www.finncap.com Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking Tel: +44 (0) WG Partners 203 705 9318 David Wilson Tel: +44 (0) Nigel Barnes 203 705 9217 Claes Spang www.wgpartners.co.uk Media Enquiries Tel: +44 (0) FTI Consulting 203 727 1000 Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities / person closely associated ------- ----------------------------------------------------------------------------------------------------------------------------- a) Name Michael Albin ------- ---------------------------- ----------------------------------------------------------------------------------------------- 2. Reason for the Notification ------- ----------------------------------------------------------------------------------------------------------------------------- a) Position/status Non - Executive Director ------- ---------------------------- ----------------------------------------------------------------------------------------------- b) Initial Initial notification notification/Amendment ------- ---------------------------- ----------------------------------------------------------------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ------- ----------------------------------------------------------------------------------------------------------------------------- a) Name Avacta Group Plc ------- ---------------------------- ----------------------------------------------------------------------------------------------- b) LEI 2138009U3EG31OPMGH36 ------- ---------------------------- ----------------------------------------------------------------------------------------------- 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------- ----------------------------------------------------------------------------------------------------------------------------- a) Description of Ordinary shares the Financial of 10p instrument, type of instrument ------- Identification GB00BYYW9G87 code ------- ---------------------------- ----------------------------------------------------------------------------------------------- b) Nature of the As set out in the Company's announcement of 23 February 2016, on 22 February 2016 transaction Mr Albin entered into a binding commitment to purchase new Avacta shares amounting to 50% of his contractual non-executive director fee per quarter and the New Ordinary Shares represent his investment for the period of 1 July 2017 to 30 September 2017. ------- ---------------------------- ----------------------------------------------------------------------------------------------- c) Price(s) and Price(s) Volume(s) volume(s) ---------------- -------------- 70.6 pence 5,311 ---------------- -------------- ------- ---------------------------- ----------------------------------------------------------------------------------------------- d) Aggregated information: * Aggregated volume See above * Price ------- ---------------------------- ----------------------------------------------------------------------------------------------- e) Date of the transaction 9 October 2017 ------- ---------------------------- ----------------------------------------------------------------------------------------------- f) Place of the London Stock Exchange, AIM transaction Market (XLON) ------- ---------------------------- -----------------------------------------------------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKCDPQBDDCKK
(END) Dow Jones Newswires
October 09, 2017 11:02 ET (15:02 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions